SHENGDA BIO-PHARM
60307911.434.67% ( +0.51 )
Q1 2026 Earnings
Financial report interval: 2025.12.31 - 2026.03.31
Overview: SHENGDA BIO-PHARM(603079) the Revenue is 189.22 M (-6.89%);the EBIT is 20.46 M (-32.1%);the EPS is 0.07 (-46.15%).
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
0.19B6.89%
----
----
EBIT
0.02B32.10%
----
----
EPS
0.0746.15%
----
----
Revenue
ActualEstimateUnit: CNY
qf
EBIT
ActualEstimateUnit: CNY
qf
Net income
ActualEstimateUnit: CNY
qf
EPS
ActualEstimateUnit: CNY
qf